Pharmafile Logo

Glaucoma in perspective

- PMLiVE

ICR scientists identify new way to study important driver of breast cancer

Researchers used a technique to identify specific molecular details of biotin-labelled proteins

- PMLiVE

Navigating challenges of MedTech research with rare-disease patients

Authored by: Tom Donnelly, MedTech Director and Amanda Pirraglia, Associate Director. Published in Quirk's Magazine.

Inizio

- PMLiVE

Did You Hear From Her? If Not Here’s What You Missed in Season 1 of the Award-Winning Season Podcast Series

What are some of the biggest gaps that women face in healthcare today?  “So many I could talk for hours!” said Shikha Jain, MD, FACP, President, CEO, Founder Women in Medicine....

Medscape Education

- PMLiVE

Have you heard from her?

We’re referring to the renowned women leaders from across the healthcare landscape who were our guests on Season 1 of Medscape Education’s Hear From Her podcast series. The conversations touched...

Medscape Education

- PMLiVE

Ipsen’s Onivyde regimen granted FDA approval to treat pancreatic cancer

Around 60,000 people are diagnosed with pancreatic adenocarcinoma in the US every year

Biogen Idec building

Biogen receives EC approval for Skyclarys in Friedreich’s ataxia patients

The company gained access to the drug through its $7.3bn acquisition of Reata Pharmaceuticals

- PMLiVE

MHRA launches second phase of genetic biobank for stroke prevention medicines

The Yellow Card Biobank will begin investigating direct oral anticoagulants such as apixaban

- PMLiVE

New type of inhibitor drug could prevent microvascular diabetic complications

The drug could prevent conditions including diabetic eye and kidney disease in diabetes

Diversity icons in Cuttsy+Cuttsy branded shapes

Clinical trial considerations: Why diversity matters…

Diversity in clinical trials is crucial for understanding diseases and developing new treatments. Here's why diversity matters...

Cuttsy + Cuttsy

- PMLiVE

Gilead expands liver disease pipeline with $4.3bn CymaBay acquisition

The deal gives the company access to a candidate being evaluated in primary biliary cholangitis

EU flag

EC approves Vertex/CRISPR’s Casgevy gene therapy for inherited blood disorders

There are now more than 8,000 patients who are potentially eligible for treatment with Casgevy

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links